Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation develops infectious-disease therapeutics centered on chronic hepatitis B, including imdusiran (AB-729), a GalNAc-conjugated RNAi therapeutic, and AB-101, an oral PD-1 inhibitor. News for ABUS commonly covers clinical data, regulatory designations such as FDA Fast Track for imdusiran, scientific-meeting abstracts, and corporate updates tied to the company’s cHBV programs.
Recurring coverage also includes financial results, capital-allocation updates, licensing revenue from lipid nanoparticle technology, and intellectual-property developments involving Arbutus and its licensee Genevant Sciences. The company’s LNP delivery technology and related patent matters are a recurring business theme alongside its clinical-stage antiviral pipeline.
Arbutus Biopharma (ABUS) reported Q3 2024 financial results with a net loss of $19.7 million ($0.10 per share). Revenue decreased to $1.3 million from $4.7 million in Q3 2023. The company maintains a strong cash position of $130.8 million, expected to fund operations into Q4 2026.
Clinical progress includes promising data from the IM-PROVE I Phase 2a trial, where 33.3% of patients achieved HBsAg loss. The company's oral PD-L1 inhibitor, AB-101, showed positive safety data and dose-dependent receptor occupancy in healthy subjects, now advancing to cHBV patient dosing.
Arbutus Biopharma (Nasdaq: ABUS) has announced it will release its third quarter 2024 financial results and provide a corporate update on Wednesday, November 6, 2024. The company will issue a press release at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET. Arbutus is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) through its pipeline of compounds, including the RNAi therapeutic imdusiran and oral PD-L1 inhibitor AB-101.
Arbutus Biopharma (Nasdaq: ABUS) announced that clinical data for imdusiran, an RNAi therapeutic for chronic hepatitis B virus (cHBV) infection, will be presented in four posters at the AASLD - The Liver Meeting® 2024. Two late-breaking posters will feature data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
Key findings from regular abstracts include:
- Imdusiran with interferon treatment showed distinct phases of immune biomarker signatures, with Th1 activation during imdusiran lead-in and Th2 signatures associated with HBsAg seroconversion.
- The imdusiran target site is highly conserved in cHBV subjects, with in vitro testing confirming activity against tested variants.
Imdusiran is designed to reduce all HBV viral proteins and antigens, potentially enabling immune system reawakening. It is currently in multiple Phase 2a clinical trials.
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference. The company will present a fireside chat on October 8, 2024, at 1:30 pm ET.
Investors and interested parties can access the live webcast of the fireside chat through the Arbutus website at https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the company's website for a time after the event. Arbutus will also host one-on-one meetings during the conference.
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in two upcoming investor conferences in New York:
1. H.C. Wainwright 26th Annual Global Investment Conference: Formal presentation on September 9, 2024, at 8:00 am ET
2. Baird Global Healthcare Conference: Fireside chat on September 10, 2024, at 8:30 am ET
The Arbutus management team will participate in and host one-on-one meetings at both events. Interested parties can access live webcasts of the presentation and fireside chat through the company's investor relations website. Archived replays will be available for a time after the events.
Arbutus Biopharma (ABUS) reported Q2 2024 financial results and provided updates on its hepatitis B virus (HBV) clinical programs. Key highlights include:
1. Positive data from two Phase 2a trials of imdusiran, showing 33% of patients achieved undetectable HBsAg after 48 weeks of treatment.
2. Company is prioritizing imdusiran's Phase 2b development and discontinuing HBV discovery efforts, resulting in a 40% workforce reduction.
3. Cash runway extended into Q4 2026.
4. Q2 revenue was $1.7 million, down from $4.7 million in Q2 2023.
5. Net loss of $19.8 million ($0.11 per share) compared to $17.1 million ($0.10 per share) in Q2 2023.
6. Cash, cash equivalents, and investments totaled $148.5 million as of June 30, 2024.
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced the schedule for its second quarter 2024 financial results and corporate update. The company will release its Q2 2024 press release on Thursday, August 1, 2024, at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET on the same day.
Interested parties can register for the conference call using the provided link. Additionally, a live webcast of the conference call will be accessible through the Investors section of Arbutus' website, with an archived version available after the event.
Arbutus Biopharma (Nasdaq: ABUS) has announced promising new data presented at the European Association for the Study of the Liver (EASL) Congress regarding its RNAi therapeutic, Imdusiran, combined with the T-cell stimulating immunotherapeutic VTP-300. The Phase 2a trial showed significant reductions in Hepatitis B surface antigen (HBsAg) levels. At 24-weeks post end-of-treatment, 94% of patients in the treatment arm achieved HBsAg levels 100 IU/mL, with 36% achieving <10 IU/mL. The treatment was generally safe, with no serious adverse events reported. The trial's results highlight the potential for Imdusiran and VTP-300 to enhance immune responses and reduce HBsAg in chronic hepatitis B patients.
Arbutus Biopharma (Nasdaq: ABUS) reported promising data from its Phase 2a trial (IM-PROVE I) for imdusiran in treating chronic hepatitis B virus (cHBV). Imdusiran, combined with interferon (IFN) and nucleoside analogue (NA) therapy, led to sustained undetectable HBsAg levels in 33.3% of patients (48-week imdusiran+24-week IFN) and 23.1% (24-week imdusiran+24-week IFN). Six patients remained HBsAg and HBV DNA-free off all therapy, with two maintaining this status for 12 weeks. The treatment was well-tolerated, with transient ALT elevations and injection site bruising as the most common adverse events. These results were presented at the EASL Congress 2024, showcasing imdusiran's potential for a functional cure for cHBV.
Arbutus Biopharma (Nasdaq: ABUS) announced it will participate in the Jefferies Global Healthcare Conference in New York. The company's management team is scheduled to present and hold one-on-one meetings with investors on June 5, 2024, at 9:30 am ET. Arbutus is focused on developing a functional cure for chronic hepatitis B (cHBV). A live webcast will be available, with an archived replay accessible on the Arbutus website for a time.